Special Report

Cannabis and the Legal Industry: New Rules, New Risks, New Opportunities

The state-by-state legalization of marijuana for medical and recreational use has created a complicated legal landscape—and with it new demands for lawyers to responsibly advise cannabis clients and companies in adjacent industries. This special report features Law.com's in-depth coverage of emerging legal issues, key regulatory developments, and the lawyers who are helping to shape a new industry.

X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

CBD OilSeven months ago, Congress enacted the Agriculture Improvement Act of 2018 (the 2018 Farm Bill). Although referred to as a farm bill, the implications for America beyond the farming community are significant. Most notably, as a consequence of the 2018 Farm Bill, hemp is no longer a controlled substance. But the fact that hemp is no longer a controlled substance does not take products that contain it out of federal regulation. The Food and Drug Administration (FDA) has regulated, and for the foreseeable future will continue to regulate, how these products can be marketed.

The FDA does not currently have an established policy for products that contain hemp beyond its standard policies for addressing foods and drugs that are marketed to consumers. Mindful that there has been a recent proliferation of these type of products and states have been encouraging companies to bring these products to market, the FDA is now soliciting comments on how to treat products that contain hemp. However, the enactment of the 2018 Farm Bill did not halt the FDA’s practice of issuing warning letters to companies that it believes are improperly marketing their products in contravention of the Food, Drug, and Cosmetic Act (FD&C Act).

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Drug and Medical Device Product Liability DeskbookBook

This timely guide covers all aspects of litigation involving drugs, medical devices, vaccines and other FDA-regulated prescription products.

Get More Information
 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.